ArticleJournal of translational medicine2026
Single-cell and spatial transcriptomic analysis reveals PAX5's role and regulatory mechanisms in gastric adenocarcinoma lymph node metastasis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundLymph node metastasis (LMN) is a key factor in the poor clinical prognosis of patients with gastric adenocarcinoma (GAC), but the underlying cellular regulatory networks and molecular mechanisms are not fully understood.
methodsA combined approach of single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) was employed to characterize the cellular landscape of the GAC lymph node metastasis microenvironment. Critical regulatory genes were screened. Their roles and underlying molecular mechanisms were then confirmed via in vitro and in vivo functional assays.
resultsEight core cell types were identified by scRNA-seq, with proliferative cell clusters further subdivided into six proliferative subpopulations, including proliferative B cells. ST revealed the presence of tertiary lymphoid structures (TLS) formed by T/B cell aggregates within tumor regions of each lesion. Proliferative B cells exhibited dynamic functional transitions. During the primary lesion (PL) stage, their function was primarily associated with regulating apoptosis. In the metastatic primary lesion (MPL) stage, this shifted to participating in T cell/NK cell activation. In the metastatic lymph node (MLN) stage, an immune evasion network was constructed through pathways such as mediating Th2-biased immune responses and uncontrolled somatic diversification of immune receptors. Lasso regression combined with a random forest model confirmed PAX5 as a highly significant regulatory gene for predicting the functional characteristics of proliferative B cells. Its expression levels progressively increased with tumor metastasis (MLN > MPL > PL, p < 0.0001). In vivo and in vitro studies confirmed PAX5’s pro-tumorigenic role, promoting proliferation by activating PI3K/AKT1 signaling and upregulating VEGF-C.
conclusionsThe systematic characterization of proliferative B cell functional dynamics, from anti-tumor immunity to immune evasion, was achieved. PAX5 was confirmed as a critical regulator of proliferative B cell function, mediating tumor progression through the VEGF-C/PI3K/AKT1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.